Aurora Cannabis Rolls Out Dried Flower, Pre-Rolls and Pastilles Globally by June
Aurora Cannabis plans to roll out a broader range of GMP-certified medical cannabis formats, including dried flower, pre-rolls and pastilles, across Canada, Europe and Australia through June. In Europe, the company will introduce new high-THC cultivars in Germany and an expanded potency range in Poland to meet rising patient demand.
1. Global Product Launch
Aurora Cannabis has scheduled a global launch of new medical cannabis offerings through June, introducing dried flower, pre-rolls and pastilles across Canada, Europe and Australia. This expansion targets patient and prescriber demand for diverse formats and aims to strengthen the company’s position in regulated markets worldwide.
2. European Market Expansion
In Germany, Aurora will debut high-THC cultivars to address growing demand for stronger medical products, while in Poland the company is expanding its potency range to cater to varied patient needs. These targeted launches are expected to enhance market share in two of Europe’s key medical cannabis markets.
3. Manufacturing and Quality Assurance
All products will be produced in Aurora’s GMP-certified facilities to ensure consistent quality, safety and supply reliability. The unified manufacturing network supports scalable production and regulatory compliance across multiple jurisdictions.